Knowledge Action Portal on NCDs

1 Resources
Short
<!-- THEME DEBUG --> <!-- THEME HOOK: 'field' --> <!-- FILE NAME SUGGESTIONS: ▪️ field--node--title--news-and-events.html.twig ✅ field--node--title.html.twig ▪️ field--node--news-and-events.html.twig ▪️ field--title.html.twig ▪️ field--string.html.twig ▪️ field.html.twig --> <!-- 💡 BEGIN CUSTOM TEMPLATE OUTPUT from 'themes/custom/whokap/templates/field/field--node--title.html.twig' --> MPP signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia <!-- END CUSTOM TEMPLATE OUTPUT from 'themes/custom/whokap/templates/field/field--node--title.html.twig' -->

Medicines Patent Pool

MPP signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

On the side lines of the World Cancer Congress 2022, the Medicines Patent Pool (MPP) announced the signing of a voluntary licensing agreement with Novartis A..

News

02 Sep 2024

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Read More